VESSL Therapeutics
Regenerative Medicine for Cardiovascular Diseases
Company Overview
Snapshot
Founded in October 2000 by Elad Tamir, Moshe Flugelman, and Basil Levis, VESSL Therapeutics operates with 1–10 employees. The company has raised $30 million across two funding rounds from seven investors.
Business overview
VESSL Therapeutics is a Health Tech & Life Sciences company focused on developing cell-based therapies for cardiovascular and other vascular-related conditions. The company's core technology integrates cell and gene therapy, utilizing patients' own cells activated by specific genes. Its leading products, MultiGeneAngio and MultiGeneGraft, are designed to treat peripheral artery disease, coronary artery disease, and renal disease requiring hemodialysis, serving the pharmaceuticals and cardiology sectors.
Strategic signal
VESSL Therapeutics ceased operations in June 2026, indicating a significant shift in its corporate trajectory. This development signals to investors and innovation teams that the company is no longer actively pursuing its regenerative medicine initiatives for cardiovascular diseases, marking an end to its efforts in this specialized market.
Log in to access full profile ›Company Intelligence Q&A
- What is the current operational status of VESSL Therapeutics?
- VESSL Therapeutics ceased to operate in June 2026.
- When was VESSL Therapeutics founded and by whom?
- VESSL Therapeutics was founded in October 2000 by Elad Tamir, Moshe Flugelman, and Basil Levis.
- What are VESSL Therapeutics' primary product offerings?
- VESSL Therapeutics' primary products include MultiGeneAngio and MultiGeneGraft, which are cell and gene therapy combinations for cardiovascular and vascular-related conditions.